YK Bioventures Opportunities Fund I, L.P. 4
4 · CERO THERAPEUTICS HOLDINGS, INC. · Filed Dec 13, 2024
Insider Transaction Report
Form 4
Transactions
- Sale
Common Stock
2024-12-12$0.07/sh−1,614,541$113,018→ 16,004,077 total(indirect: By YK Bioventures Opportunities Fund I, L.P.) - Sale
Common Stock
2024-12-11$0.08/sh−1,343,801$107,504→ 17,618,618 total(indirect: By YK Bioventures Opportunities Fund I, L.P.) - Sale
Common Stock
2024-12-13$0.06/sh−2,998,908$179,934→ 13,005,169 total(indirect: By YK Bioventures Opportunities Fund I, L.P.)
Footnotes (1)
- [F1]Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein.